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Abstract
Conflicting prevalence of newly identified KI(KIPyV), WU(WUPyV) and Merkel Cell Carcinoma(MCPyV) polyomaviruses have
been reported in progressive multifocal leukoencephalopathy(PML) patient samples, ranging from 0 to 14.3%. We analyzed
the prevalence of these polyomaviruses in cerebrospinal fluid(CSF), peripheral blood mononuclear cells(PBMC), and bone
marrow samples from PML patients, immunosuppressed individuals with or without HIV, and multiple sclerosis(MS)
patients. Distinct PCR tests for KIPyV, WUPyV and MCPyV DNA performed in two independent laboratories detected low
levels of MCPyV DNA only in 1/269 samples. The infrequent detections of these viruses in multiple samples from
immunosuppressed individuals including those with PML suggest that their reactivation mechanisms may be different from
that of JC polyomavirus (JCPyV) and that they do not play a role in the pathogenesis of PML.
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Introduction
Three new human polyomaviruses have been identified, KIPyV
[1], WUPyV [2] and MCPyV [3]. Recent serological data have
shown that in an adult population, seropositivity for KIPyV
ranged from 63.3% to 70%, and for WUPyV ranged from 80%–
100% [4]. While KIPyV and WUPyV were mainly detected in
respiratory tract secretions in children, MCPyV was associated
with a rare tumor of the skin called Merkel Cell Carcinoma.
Further epidemiological investigations demonstrated that KI and
WU PyV were predominantly found in patients with respiratory
symptoms [5,6], while MCPyV was also detected in the respiratory
tract of children and immunosuppressed adults [5]. Therefore, a
clear link between these polyomaviruses and a specific disease has
yet to be established [7]. Several published reports investigated the
possible pathogenic roles of the new polyomaviruses in blood,
lymphoid tissue, and central nervous system (CNS) samples from
immunosuppressed patients, including those with PML [7–14],
showed discrepant results. Whereas one study reported detecting
KIPyV and WUPyV in 14.3% of the brain samples from HIV-
positive patients with PML [8], another study did not detect any of
the three new polyomaviruses in the brain samples from HIV-
positive patients with PML [9](Table 1). To clarify these
conflicting results, we first performed a literature search and
summarized all published findings in detection of KI, WU,
MCPyVs in non respiratory samples of adult patients. Using
different PCR methods at two distinct laboratories, we then
screened for the three new polyomaviruses in 269 samples from
123 adult patients including HIV-positive with and without PML,
HIV-negative with PML, multiple sclerosis (MS), other immuno-
suppressed patients and 2 HIV-negative immunocompetent
patients with other neurological syndromes (ONS).
Results
Laboratory 1 did not detect any of the 3 polyomaviruses DNA
by PCR in all samples tested. Likewise, laboratory 2 also did not
detect any positive sample for KIPyV and WUPyV among the 156
samples tested (Table S1, S2, S3, S4, S5, S6). There was one
positive detection of MCPyV in the CSF from 36 samples in the
immunosuppressed group (Table 2). This singular MCPyV
positive produced a late cycle threshold value of 34.8, which is
suggestive of a very low viral load.
We have analyzed 8 published studies of detection of KI, WU
and MC PyVs in CNS/blood/lymphoid tissue samples of adult
patients (Table 1). 24 different primer sets were used in 21
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plasma, blood, CSF, brain biopsy and autopsy tissues, and autopsy
lymphoid tissues. In all but one study, the healthy control group
did not have any samples that contained detectable KI, WU, and
MC PyV DNA. In the study by Sharp et al 1 healthy control had
detectable KIPyV DNA and 1 healthy control had detectable
MCPyV DNA [10]. However, unlike other reports, this study
included HIV-positive, non AIDS patients in the healthy control
group. In the ‘‘other (non-HIV) immunosuppressed’’ group, 3
studies reported no detection of any of the 3 new polyomaviruses,
while one study detected WUPyV in 2.5% of patients with
hepatitis C [11]. In the HIV-positive group, all studies detected at
least one of the three polyomaviruses in at least one sample.
Detection of KIPyV and WUPyV in HIV-positive PML patients
Table 1. Reported prevalence of new polyomaviruses in immunosurpressed and immunocompetent individuals.
Virus Name HIV+/PML
HIV+ w/o
PML
Other Immuno-
supressed Hepatitis C+ CTRL Specimen type Reference
KIPyV N/A 3/42 (7.1%) N/A N/A 1/55 (1.8%) 97 Lymphoid tissue [10]
N/A 0/6 N/A N/A 0/54 60 CSF [13]
2/14 (14.3%) 6/25 (24%) N/A N/A 0/15 54 Brain tissue [8]
N/A N/A 0/68 N/A N/A 19 blood+49 lymph node [15]
0/7 N/A N/A N/A N/A 7 Brain tissue [9]
N/A 1/100 (1%) 0/100 N/A 0/100 300 blood [14]
N/A N/A N/A N/A 0/300 300 Brain tissue [16]
N/A 4/153 (2.6%) N/A N/A N/A N/A [12]
WUPyV N/A 3/42 (7.1%) N/A N/A 0/55 97 Lymphoid tissue [10]
N/A 1/6 (16.7%) N/A N/A 0/54 60 CSF [13]
2/14 (14.3%) 4/25 (16%) N/A N/A 0/15 54 Brain tissue [8]
N/A N/A 0/68 N/A N/A 19 blood+49 lymph node [15]
0/7 N/A N/A N/A N/A 7 Brain tissue [9]
N/A 1/100 (1%) 0/100 N/A 0/100 300 blood [14]
N/A 10/121 (8.3%) N/A 2/79 (2.5%) 0/120 320 Serum [11]
N/A N/A N/A N/A 0/300 300 Brain tissue [16]
N/A 7/153 (4.5%) N/A N/A N/A N/A [12]
MCPyV N/A 0/42 N/A N/A 1/55 (1.8%) 97 Lymphoid tissue [10]
N/A 0/6 N/A N/A 0/54 60 CSF [13]
N/A N/A N/A N/A N/A 54 Brain tissue [8]
N/A N/A 0/68 N/A N/A 19 blood+49 lymph node [15]
0/7 N/A N/A N/A N/A 7 Brain tissue [9]
N/A N/A N/A N/A N/A 300 blood [14]
N/A N/A N/A N/A 0/300 300 Brain tissue [16]
PML: progressive multifocal leukoencephalopathy; HIV+: HIV positive; w/o: without; CTRL: control; N/A: specimens not available; CSF: cerebral spinal fluid; KIPyV: KI
polyomavirus; WUPyV: WU polyomavirus; MCPyV: Merckel cell carcinoma polyomavirus.
doi:10.1371/journal.pone.0016736.t001
Table 2. Summary of screening results of new polyomavirus from both laboratories.
Virus name PML HIV-positive MS
Other
Immunosuppressed
Hepatitis C
Virus-positive ONS Result source
HIV-positive HIV-negative
KIPyV 0/50 0/30 0/36 0/115 0/36 N/A 0/2 Laboratory 1
0/50 0/30 0/36 0/2 0/36 N/A 0/2 Laboratory 2
WUPyV 0/50 0/30 0/36 0/115 0/36 N/A 0/2 Laboratory 1
0/50 0/30 0/36 0/2 0/36 N/A 0/2 Laboratory 2
MCPyV 0/50 0/30 0/36 0/115 0/36 N/A 0/2 Laboratory 1
0/50 0/30 0/36 0/2 1/36 (2.8%) N/A 0/2 Laboratory 2
Total: 269 samples from 123 patients.
PML: progressive multifocal leukoencephalopathy; ONS: other neurological syndromes; N/A: specimens not available; MS: multiple sclerosis; KIPyV: KI polyomavirus;
WUPyV: WU polyomavirus; MCPyV: Merckel cell carcinoma polyomavirus.
doi:10.1371/journal.pone.0016736.t002
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examined samples from the HIV-negative PML group, or patients
with multiple sclerosis.
Discussion
Our largely negative results suggest that the new human
polyomaviruses WU, KI are not commonly found in the CNS,
urine and blood of HIV-positive and MS patients, including those
treated with natalizumab, and that immunosuppression does not
result in replication and detection of these viruses in multiple
compartments. Likewise, MCPyV was rarely detected in all
populations. However, its detection in the CSF of an immuno-
suppressed patient may suggest neurotropic features of this virus,
which is associated with a neuroendocrine tumor.
Overall, our data is in accordance with previously published
studies, indicating that the novel human polyomaviruses are not
typically detected in the CNS, blood and urine of HIV-positive and
HIV-negative immunosuppresed patients (Table S2, S5). There-
fore, whereas immunosuppression can cause reactivation of JCPyV
and BKPyV resulting in increased detection of these viruses,
immunosuppression does not seem to affect the reactivation and
thus the detection of WU, KI, and MCPyV. A recent study did not
find any difference in the prevalence of WU and KIPyV DNA
detection in plasma of HIV-positive patients after grouping the
patients by their CD4 counts [12]. By including HIV-negative
immunosuppressed patients in our study (Table S2, S5), we have
further explored whether immune dysfunction in addition to CD4
counts can affect the detection of these polyomaviruses.
Our results differed from the reported positive rate of KIPyV
and WUPyV in immunosuppressed patients [8,10,13,14]. Indeed,
our data showed that the three new human polyomaviruses, aside
from one exception, were not detected in CSF, brain biopsy, urine,
bone marrow, and PBMC of PML patients with or without HIV
and MS patients (Table S1, S2, S3). This differed from the study
by Barzon et al [8] where 14.3% of the samples from PML
patients had detectable KI and WU PyV, but is consistent with the
findings of Focosi et al [9] and Maggi et al [15], who also reported
no KIPyV and WUPyV DNA in PML and other immunosup-
pressed patients. Moreover, our results are also supported by the
findings by Lam et al [16], who did not detect KIPyV, WUPyV
and MCPyV in 300 brain samples from 30 individuals (Table S2).
Lastly, our study is the first to include results from two different
laboratories using different PCR methods, thereby confirming the
study findings.
For the first time, we have also examined the prevalence of these
new polyomaviruses in patients with multiple sclerosis (Table S3).
The 113 samples from MS patients were collected both pre- and
post-natalizumab treatment, providing an opportunity to investi-
gate possible effects on DNA detection of new polyomavirus after
blockade of alpha 4 integrin receptors. We have previously shown
that up to 60 percent of these MS patients had evidence of JCPyV
reactivation in blood samples during natalizumab treatment, while
they all remained BK virus (BKPyV) negative [17]. In this current
study we did not detect DNA from KIPyV, WUPyV, and MCPyV
in the same samples in these patients. Although JCPyV
reactivation in natalizumab treated MS patients remains contro-
versial [18], results in this study suggested that there was no co-
reactivation of new PyVs with JCPyV in our cohort of MS patients
treated with natalizumab. These results also provide evidences that
the pathogenesis of these three new polyomaviruses may be more
closely related to BKPyV than JCPyV.
Our screening for DNA of MCPyV was positive in only 1/36
(2.8%) CSF samples from the HIV-negative immunosuppressed
group without PML (Table 2), which differed from the results from
another study [15] . Absence of KIPyV and WUPyV also differed
from data published by other groups [8,10,13,14]. These
conflicting results may be due to geographical diversity in the
patient or in the viral populations, and the different laboratory
methods used in the various studies. Indeed, the sensitivity of PCR
assays can be affected in part by sequence variation and methods.
Collaborative investigations and standardization of detection
methods will be important to help understand the true prevalence
of new polyomaviruses in clinical samples from different
geographic origins.
Lastly, our results and other studies did not find any clear
associations between KI, WU, and MC PyV detection in human
samples and immune suppression due to HIV, or immune
dysregulation due to MS and its treatment. In our study, WU,
KI, and MC PyV were generally not detected in a wide range of
immunosuppressed patient samples, particularly within the CNS
and blood. These results suggest that in addition to different viral
tropism, the mechanisms of viral pathogenesis in latency and
reactivation differs significantly among the various human
polyomaviruses.
Materials and Methods
Samples were collected from patients seen at Beth Israel
Deaconess Medical Center, Boston, MA. Study was approved by
the Institutional Review Board.
A total of 269 samples were collected from 123 patients from 6
groups: HIV-positive with PML, HIV-negative with PML, HIV-
positive, MS, other immunosuppressed patients and patients with
ONS (Tables S1, S2, S3, S4, S5, S6). Samples contained 8 brain
autopsy tissues from 6 patients (6 from 5 HIV-positive patients
with PML, 2 from a patient with chronic lymphocytic
leukemia(CLL)), 62 CSF samples from 59 patients (30 from 29
HIV-positive patients with PML, 12 from 12 HIV-negative
patients with PML, 6 from 6 HIV-positive patients, 10 from 10
patients immunosuppressed by other diseases and 2 from 2 MS
patients), 13 whole blood samples from 13 patients (2 from 2
HIV-negative patients with PML, 2 from 2 HIV-positive
lymphoma patients, 3 from lymphoma patients, 2 from 2 patients
with monoclonal gammopathy of undetermined significance(M-
GUS), 1 from a patient with thrombocytosis, 1 from a HIV-
positive patient with anemia, 1 from a patient with Leshmaniasis,
1 from a CLL patient), 68 PBMC samples from 49 patients (14
from 14 HIV-positive patients with PML, 10 from 10 HIV-
negative patients with PML, 7 from 7 HIV-positive patients, 19
from MS patients prior to natalizumab treatment, 18 from MS
patients after natalizumab treatment). 47 blood plasma samples
from 28 patients (3 from 3 HIV-negative patients with PML, 3
from 3 HIV-negative lymphoma patients, 1 from 1 HIV-negative
MGUS patient, 1 from 1 HIV-positive lymphoma patient, 1 from
1 HIV-positive patient, 19 from MS patients prior to natalizumab
treatment, 19 from MS patients after natalizumab treatment). 13
bone marrow samples from 13 patients (2 from 2 HIV-negative
patients with PML, 2 from 2 MGUS patients, 2 from HIV-
negative lymphoma patients, 1 from HIV-negative Leshmaniasis
patient, 1 from HIV-negative CLL patient, 3 from HIV-positive
lymphoma patients, 1 from 1 HIV-positive patient with
thrombocytosis, 1 from 1 HIV-positive patient with anemia), 8
bone marrow plasma samples from 8 patients (2 from 2 HIV-
negative patients with PML, 3 from 3 HIV-negative lymphoma
patients, 1 from 1 HIV-negative MGUS patient, 1 from 1 HIV-
positive patient with thrombocytosis, 1 from 1 HIV-positive
lymphoma patient), 1 bone marrow PBMC sample from 1 HIV-
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patients (3 from 3 HIV-negative lymphoma patients, 2 from 2
HIV-negative MGUS patients, 1 from 1 HIV-negative patient
with Leshmaniasis, 1 from 1 HIV-positive patient with anemia, 1
from 1 HIV-positive patient with thrombocytosis, 1 from HIV-
positive lymphoma patient, 19 from 19 MS patients prior to
natalizumab treatment, and 19 from 19 MS patients after
natalizumab treatment). Two CSF samples collected from 2 HIV-
negative immunocompetent patients with ONS were also
included. All samples were stored at either 220uCo r280uC.
All 269 samples were tested for the new polyomaviruses in
laboratory 1. Of the 269 samples, 153 samples were transferred to
laboratory 2 for testing.
DNA extraction
QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA) was
used to extract DNA. DNA concentration was determined by
NanoDrop ND-1000 spectrophotometer (Thermo Scientific,
Waltham, MA).
PCR reaction
Laboratory 1 used primers POLVP1-39F(59-AAGGCCAA-
GAAGTCAAGTTC-39, KIPyV(1536-1555) and POLVP1-363R
(59-ACACTCACTAACTTGATTTGG-39, KIPyV(1860-1840)
reverse compliment(RC)) [1] for KIPyV AG0048(59-TGTTT-
TTCAAGTATGTTGCATCC-39, WUPyV 2822-2844) and
AG0049(59-CACCCAAAAGACACTTAAAAGAAA-39, WUPyV
3065-3042 RC) [2] for WUPyV and primers LT3F571 (59-
TTGTCTCGCCAGCATTGTAG-39), MCPyV (571-590) and
LT3R879 (59-ATATAGGGGCCTCGTCAACC-39. MCPyV
879-860 RC) [3] for MCPyV were used in a qualitative PCR
assays by laboratory 1 as previously described [1,2,3]. In each
reaction, 0.5 ug of DNA was used. For sample where DNA
quantification is not possible, 10 ul of the extraction mixture was
used per reaction
A triplex real time PCR was used by laboratory 2 to detect KIPyV
and WUPyV. A total of three sets of primer pairs and probes
were used in the reaction: set # 1: Primer KI-D-F(59-CA-
CAGGTGGTTTTCTATAAATTTTGTACTT-39. KIPyV 4524-
4553), primer KI-D-R(59-GAAGCAGTGGGATGTATGCATTC-
39, KIPyV 4635-4613 RC), probe KI-D-Pr (59-HEX-TGCATTGG-
CATTCGTGATTGTAGCCA-BHQ1-39, KIPyV 4586-4611); set
# 2: primer KI-E-F (59-GAACTTCTACTGTCCTTGACA-
CAGGTA-39, KIPyV 247-273), primer KI-E-R (59-GGATTA-
GAACTTACAGTCTTAGCATTTCAG-39, KIPyV 345-316 RC),
probe KI-E-Pr (59-Quasar 670-TGGGAAACATCCGGTTT-
CCTCTCACTTCC-BHQ2-39, KIPyV 316-345); set # 3: primer
WU-F-F (59-GCCGACAGCCGTTGGATATA-39, WUPyV 531-
550), primer WU-F-R (59-TTTCAGGCACAGCAAGCAAT-39,
WUPyV 601-582 RC), probe WU-F-Pr (59-FAM-AGGGTCAC-
CATTTTTATTTCAGATGGGCA-BHQ1-39, WUPyV 552-580).
For MCPyV detection, primer MCV-1.1-F(59-AGCTCAGAAGT-
GACTTCTCTATGTTTGA-39, MCPyV 398-425), primer MCV-
1.1-R(59-ACAATGCTGGCGAGACAACT-39, MCPyV 588-569
RC) and probe MCV-1.1-Prb(59-JOE-TTTGCAGAGGTCCTG-
GGTGCATG-BHQ1-39, MCPyV 503-525) were used in the first
round detection and then confirmed by MCV2.0 primer and probe
set (primer MCPyV-2.0-4367F: 59-GGCAGCATCCCGGCTTA-
39, primer MCPyV-2.0-4399R: 59-CCAAAAAGAAAAGCAT-
CATCCA-39,probe MCPyV-2.0-4371-Prb:59-FAM-ATACATTG-
CCTTTTGGGTGTTTT-BHQ1-39) as described previously [6].
The PCR reactions consisted of 12.5 mlQ u a n t i t e c tP r o b eP C R
Mix (QIAGEN, Australia), 10 pmol of each primer, 4 pmol of
each probe and 2 ml of template in a 25 ml final reaction, which
was performed in either a Rotorgene 3000 or Rotorgene
6000(Corbett Research, Sydney, Australia) under the following
conditions: 15 minutes incubation at 95uC, followed by 50 cycles
of 95uC for 15 seconds and 60uC for 1 minute. PCR sensitivity
was 10 copies per reaction.
Plasmids containing KIPyV, WUPyV and MCPyV genome
(generous gifts from Dr. Tobias Allander of Karolinska Institute,
Dr. David Wang of Washington University School of Medicine
and Dr. Huichen Feng of University of Pittsburgh) were used as
positive controls in Laboratory 1, while Laboratory 2 used clinical
samples containing WU, KI and MC PyV DNA confirmed by
sequencing.
Literature search
PubMed searches were performed using terms ‘‘human
polyomavirus’’ and ‘‘detection’’. Only papers in English language
and studies with adult patients were reviewed, and studies using
respiratory samples were excluded.
Supporting Information
Table S1 Summary of all samples. All 269 samples were
categorized into PML, MS and non-PML/non-MS groups in
Table S1A. All 269 samples were categorized into immunosup-
pressed and immunocompetent groups in Table S1B.
(DOC)
Table S2 Samples from PML patients (80 samples from
61 patients).
(DOC)
Table S3 Samples from MS patients (115 samples from
21 patients).
(DOC)
Table S4 Samples from non-PML, non-MS patients (74
samples from 41 patients).
(DOC)
Table S5 Samples from Immunosuppressed patients
(113 samples from 90 patients).
(DOC)
Table S6 Samples from Immunocompetent patients
(156 samples from 33 patients).
(DOC)
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